The autoimmune disease diagnostics market size was exhibited at USD 5.85 billion in 2023 and is projected to hit around USD 10.68 billion by 2033, growing at a CAGR of 6.2% during the forecast period 2024 to 2033.Increasing prevalence of autoimmune disorders such as type 1 diabetes in newborn babies coupled with demand for rapid diagnostics is the key driver accentuating growth.
| Report Coverage | Details |
| Market Size in 2024 | USD 6.21 Billion |
| Market Size by 2033 | USD 10.68 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 6.2% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Type ,Regional |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd; Siemens Healthineers; Abbott Laboratories; Beckman Coulter, Inc.; SQI Diagnostics; Quest Diagnostics; EUROIMMUN AG; AESKU.Diagnostics GmbH & Co. KG; INOVA Diagnostics, Inc.; Crescendo Bioscience, Inc.; bioMerieux SA; Bio-Rad Laboratories, Inc.; and Hemagen Diagnostics, Inc. |
Research and diagnostics institutes over the globe are undertaking initiatives in compliance with government organizations owing to the rising prevalence of autoimmune disorders and the consequent rise in healthcare expenditure. According to the data published by the National Institutes of Health (NIH), these disorders have been ranked as one of the top ten disorders leading to increased mortality rates among women.
The introduction of technological advancements and increasing lab automation rates are estimated to fuel market growth. Clinicians are adopting advanced technology in order to conduct multiple tests at the same time with faster and more precise results.
Slow turnaround time associated with the usage of conventional disease diagnostic techniques and the presence of a lesser number of standardized tests for over 80 disease types are some of the shortcomings encouraging laboratories to move toward automation.
Moreover, the presence of favorable government initiatives is anticipated to positively boost market dynamics. Organizations such as the Autoimmunity Centers of Excellence, Cooperative Study Group for Autoimmune Disease Prevention, and North American Rheumatoid Arthritis Consortium are actively involved in educating patients and healthcare professionals regarding proper diagnosis and treatment.
Growing awareness amongst patients concerning these diseases is expected to drive the market growth. Survey results conducted by the American Autoimmune Related Diseases Association, Inc. (AARDA) in 2013 suggest that the ability of an American patient to name an autoimmune disease has increased by 10% (as compared to the last conducted survey).
This increase can be attributed to extensive public awareness campaigns undertaken such as the Autoimmune Awareness Month held in March 2023 and National Awareness Campaign by the AARDA.
On the basis of type, autoimmune diseases are segmented into localized and systemic disorders.
Localized disease diagnostics dominated the overall market in terms of revenue in 2023. The presence of large procedure volumes and relatively higher (in comparison with systemic diseases) patient awareness level are some of the factors accounting for its large share.
On the other hand, systemic disease diagnostics are expected to witness the fastest growth over the forecast period on account of the implementation of favorable government initiatives, especially the AMP RA/SLE program for patients suffering from rheumatoid arthritis and systemic lupus erythematosus.
The program is anticipated to provide a platform for the development of novel therapeutics and the generation of publicly accessible precompetitive and disease-specific databases for further research usage.
North America held the largest market share of over 45.0% in 2023, majorly due to the introduction of the Affordable Care Act, the presence of favorable regulations & initiatives undertaken by the AARDA, and high disease prevalence in the region.
According to AARDA, nearly 50 million Americans have some form of autoimmune disorder. A high prevalence of these diseases along with healthcare expenditure has triggered the introduction of favorable initiatives by the government and other industry-friendly organizations. These initiatives aim to curb healthcare spending by diagnosing diseases at an early stage and elevating patient awareness levels.
Asia Pacific region is expected to witness lucrative growth due to constantly improving healthcare infrastructure, growing patient awareness levels, and the presence of high unmet patient needs. It is expected to experience an increase in revenue share during the forecast period. Its market share is anticipated to grow from 21.0% in 2023 to over 22.0% in 2033.
The market is consolidated in nature, therefore is marked by the presence of extensive mergers and acquisitions. Some key players of this market include F. Hoffmann-La Roche Ltd; Siemens Healthineers; Abbott Laboratories; Beckman Coulter, Inc.; SQI Diagnostics; Quest Diagnostics; EUROIMMUN AG; AESKU.Diagnostics GmbH & Co. KG; INOVA Diagnostics, Inc.; Crescendo Bioscience, Inc.; bioMerieux SA; Bio-Rad Laboratories, Inc.; and Hemagen Diagnostics, Inc.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the autoimmune disease diagnostics market
Type
Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers